Print Page | Sign In | Join ISSX
High Throughput ADME Bioanalysis - It's a Sprint, Not a Marathon
Share |

High Throughput ADME Bioanalysis - It's a Sprint, Not a Marathon

Presented by: Lance Heinle, AbbVie and John Janiszewski, NCATS

Thursday, June 18, 2020

View the Recording        View the Slides        Past Webinars


The use of in vitro ADME (absorption, distribution, metabolism, and excretion) data to drive candidate selection plays a vital role in the drug discovery process. Just as important is the need to provide this data in a timeframe that keeps up/coincides with chemistry efforts, as some companies can synthesize up to 1,000 new molecular entities each week.

To aid in candidate selection, many companies employ an initial suite of in vitro ADME assays (Tier 1) to run on each new molecule, giving teams a baseline of information from which to promote promising candidates to either in vivo studies or a second series of tailored in vitro assays (Tier 2) for further characterization. For some companies, this can translate to  upwards of 40,000 in vitro samples each week. In this Webinar, we look to answer what technologies exist to enable the analysis of this high volume of samples each week; from sample logistics, to critical hardware and software, with a look ahead at what new innovations are on the horizon. 

About the Speakers:


Lance Heinle is a Senior Scientist II in the Drug Metabolism Department at AbbVie Inc. (Chicago), where he oversees the in vitro Bioanalytical group.  Before joining AbbVie in 2010, he spent seven years with Pfizer (St. Louis) and two years with Pharmacia and Upjohn (Kalamazoo).  Lance obtained his Bachelor’s in Chemistry from Illinois State University in 1999, followed by his Master’s in 2001.  He has published multiple journal articles in the fields of in vitro ADME methodologies and liquid chromatography-tandem mass spectrometry.

 John Janiszewski is a Research Scientist at National Center for Advancing Translational Sciences (NCATS), in Rockville, MD.  Before joining NCATS he was an Associate Research Fellow at Pfizer Inc. where he led the Bioanalytical Technology (BAT) group. John earned an M.S. degree in Chemistry at the State University of New York, College of Environmental Science and Forestry where he studied Bioanalysis of PSP and related Toxins.